DXY and commodities usually don't move in the same direction.

One of them has to give-in.

My money (not literally) is on commodities reversal in near future.

Even in the past, whenever the inverse relationship appeared to be broken, it always resolved in the favour of USD.

Reversal Stocks
Near supertrend buy
With good fundamentals

You can create amazing combos using @mystockedge
Keep it simple. Use StockEdge

Look for 178 stocks filtering out my screen of Price above 50 & 200 MA and a very strong relative strength. I run separate screeners for both of them & then find the common names. A sample for

Stan Weinstein's Ideal Short Sale areas:

Ran a screen:

1) US listing
2) Mkt cap > $500M
3) EBITDA margins >15%
4) ROE > 20%
5) 5-yr revenue and EBITDA CAGR > 5%
6) Net leverage < 3x

Far from perfect for various reasons, but solid list of quality companies to research.

Some quick observations:

Company like $HD not captured because ROE is negative (negative BV due to repo/divs).

Company like $AMZN not captured because not 15% EBITDA margin.

Highly acquisitive businesses ($CHTR, $WCN, etc.) not captured due to intangibles depressing ROE...

...this last element is a big issue I have with these screens...underlying unit economics may be excellent but GAAP accounting can obscure based on headline ROE.

End of the day, screens like this are backwards looking so far from perfect, but can glean some interesting insights.

2 more observations: great business like $COST is low margin but has high asset turns so generates high ROIC/ROE but not captured because of margin element I screened for.

Also, great businesses that can carry high leverage ($EQIX, $PLD, etc.) not captured due to leverage screen

Used Bloomberg to do this screen. Can also be done via CapIQ.

Prices fall, then, margins/topline takes beating, then, rerating normalizes, then, market loses interest, derating happens.Nothing excites - topline/margin. Market does not find quock triggers. Value emerges. Oneday triggers come, prices rise, growth comes, rerating happens

Most important candlestick patterns for stock selection:
Candlesticks are very good representation of psychology of traders in the market and hence the success rate of candlesticks pattern is very high.

Many mid and small cap stocks are in correction phase. Watch 39 EMA closely many will take support from there and bounce back.

*Focus on Good Fundamental Stocks.
*Avoid stocks which go through lower circuit in last few days.
*keep tight stoploss below 55 EMA.

Since many of you'll asked..
I love gapups upon results..I find them v powerful tools esp if they don't get filled over the first 3-5 days.
On the flip side..gapdown breakdowns are something i totally dislike..so i prefer to watch and watch...
DN, Tata Chem, Balaji

This is what a gapup breakout can potentially do..
Tesla's 10-20x move also started with a Gapup...

and before you'll start thinking gaps lead to multi bag moves..do remember..Tesla had fallen 60% before it started its move..
Most of our stocks currently already trading at rich valuations.

And lastly while on the subject of gaps..here is one which did gapdown on high volumes..
One of my biggest winners of 2020..
Never covered the gap and drifted downwards..

Just doing this as hindsight analysis to show visual examples of gapups and downs.

New Combo using @mystockedge

Stocks with low PEG ratio
High ROE
Strong Price Action

https://t.co/ld4AiwlHOd https://t.co/ED7xFBgTiS

Something based on my experience:
In a truncated week (like this week), Assets move against the trend.

So if the trend is up, in a truncated week the assets can move opposite to the trend.

#Nifty #Markets.

The Q4F22 Earnings season is almost here!

What are the Key things that you need to track in various businesses like Hospitals 🏥, Pharma🩹, Chemicals 🧪 and Music🎵 etc ⤵️⤵️

I will be analysing the companies and the expectations in two ways:-

1⃣What does the company do and the sales split?
2⃣What to expect from the results/Business direction?

1. Divis Labs:

Over the years Divis has proven its capabilities as an API player and has the highest Ebitda margins (44%) when compared to the other Pharma companies. 57% of the business in the last Quarter Q3FY22 was contributed by Synthesis and 43% by Generic API’s.

What to expect?

Molnupiravir has contributed to almost 21% of sales for Divis in FY22 (According to Kotak).
Investors will need to track the recovery in the Generic API division which has been soft for the last 3 quarters and growth in CDMO ex of Molnupiravir.

What to look for in Financials?

Key monitorable to track is by how much the topline grows or degrows QoQ. Given the base was high in last Quarter due to Molnupiravir Sales.

Topline sustaining above 2100 crores and margins above 41% will be good!